Penn uncovers dose of medication more likely to put patients with pemphigus into remission

(University of Pennsylvania School of Medicine) Researchers from Penn compare a lymphoma-dose regimen of rituximab to a rheumatoid arthritis regimen for the treatment of pemphigus.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

AbstractBackgroundBecause of the severe shortage of suitable deceased donors, ABO-incompatible living donor kidney transplantation (ABOi LDKT) is performed even in pediatric recipients in Japan. We performed pediatric ABOi LDKT using rituximab without anti-A/B antibody removal.MethodsThirteen pediatric recipients (mean age 7.4, range 3.4 –15.7, four females) whose baseline anti-A/B IgG titers were ≤ × 64 underwent ABOi LDKT without antibody removal and splenectomy between July 2013 and April 2017 at Toho University. Mycophenolate mofetil (MMF) was initiated on day − 10. Rituximab (...
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research
ConclusionAs rare as this pathology is, this article aims to improve the available data and provide useful information regarding diagnosis and therapy.ResumoIntroduçãoO linfoma do TGI pode ser dividido entre primário e secundário, com importância diagnóstica e terapêutica. O linfoma primário de reto é patologia rara, pouco relatada em literatura médica. Sua incidência tem aumentado e possivelmente esse fenômeno esteja associado ao aumento no numero de pacientes com imunossupressão (seja por SIDA ou drogas imunossupressoras).MetodologiaFo...
Source: Journal of Coloproctology - Category: Gastroenterology Source Type: research
Abstract This paper presents the first comprehensive report on traditional uses of medicinal shrubs of Rawalakot city, district Poonch, Azad Jammu and Kashmir, Pakistan. Ethobotanical data obtained from 120 informants were analyzed by relative frequency citation, use value, family use value, informant consensus factor, fidelity level and Jaccard index. In total, 41 shrubs belonging to 24 families and 34 genera were documented. Rosaceae was reported the most dominant family in the area (six species) and Berberidaceae showed maximum family use value (0.68). Leaves (35%) and fruits (33%) were the most commonly used plant part...
Source: Revista Brasileira de Farmacognosia - Category: Drugs & Pharmacology Source Type: research
Conditions:   Inflammatory Bowel Diseases;   Ulcerative Colitis;   Crohn Disease;   Arthritis, Rheumatoid;   Spondyloarthritis;   Psoriatic Arthritis Intervention:   Sponsor:   Centre Hospitalier Universitaire de Besancon Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Biphenotypic Acute Leukemia;   Undifferentiated Leukemia;   Prolymphocytic Leukemia;   Myelodysplastic Syndromes;   Chronic Myelogenous Leukemia;   Myeloproliferative Neoplasm;   Relapsed Large Cell Lymphoma;   Man tle Cell Lymphoma;   Hodgkin Lymphoma;   Burkitt Lymphoma;   Relapsed T-Cell Lymphoma;   Relapsed Chronic Lymphocytic Leukemia;   Relapsed Smal...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We aimed to assess the long-term effects and safety of RTX for the treatment of pemphigus in the Chinese population. In this retrospective study, 74 pemphigus patients treated with RTX from February 2008 to December 2018 and followed up were included and analyzed. Lymphoma protocol (LP, 375mg/m2 per week for 4 weeks) or rheumatoid arthritis protocol (RAP, 1000mg on the 1st and 15th day) was used as RTX protocol. The median follow-up duration was 26.1 months. CR rate was 66.2% and the median time to achieve CR was 11.0 months.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Adaptive Immunity and Autoimmunity Source Type: research
Conclusions The clinical trials discussed here, which include several trials investigating novel therapeutic targets, demonstrate that translational research in pemphigus and pemphigoid is a fast-growing field. We thus expect that several novel treatments will be shortly available for the treatment of pemphigus and pemphigoid patients. Given the high, and thus far unmet, medical need in this field (110), this is highly encouraging and will hopefully improve the quality of life of the affected patients. In addition to the compounds and targets described here, several new targets have been recently identified in preclinical...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Extracorporeal Photochemotherapy/Photopheresis (ECP) is considered an immunomodulating therapy with several potential clinical applications. ECP was initially developed by Edelson et al. [1] as a treatment for cutaneous T-cell lymphoma (CTCL). In 1988, the use of ECP was approved by the U.S. Food and Drug Administration as standard therapy for the treatment of patients with advanced refractory CTCL [2]. Later, ECP was used in the treatment of several autoimmune T-cell-mediated diseases such as pemphigus vulgaris [3,4], systemic sclerosis [5,6], rheumatoid arthritis [7,8], Crohn's disease [9,10] and multiple sclerosis [11].
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research
Abstract Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Chronic graft-versus-host disease and pemphigus vulgaris are two of the most promising indications for off-label use of rituximab. It is a generally safe alternative that should be considered when traditional therapy with corticosteroids or immunosuppressants has failed or caused significant intolerance. Currently, rituximab is only FDA-approved for treatment of follicular and diffuse large B-cell non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, g...
Source: Skin Therapy Letter - Category: Dermatology Authors: Tags: Skin Therapy Lett Source Type: research
Abstract This meta-analysis examined the efficacy of different dosing regimens containing rituximab (RTX) in treating pemphigus. The analysis included 578 patients with pemphigus from 30 studies. Seventy-six percent of patients achieved complete remission (CR) after 1 cycle of RTX. Mean time to remission was 5.8 months, with a remission duration of 14.5 months and a 40% relapse rate. Eighteen patients (3.3%) developed serious adverse effects. The pooled estimate showed no significant differences in CR and relapse rates between patients treated with high-dose (near or ≥ 2,000 mg) vs. low-dose (
Source: Acta Dermato-Venereologica - Category: Dermatology Authors: Tags: Acta Derm Venereol Source Type: research
More News: Arthritis | International Medicine & Public Health | Lymphoma | Pemphigus | Rheumatoid Arthritis | Rheumatology | Rituxan | University of Pennsylvania